Tags : Rejects

Pharma

NICE, UK Rejects Gilead’s Yescarta for Being Too Expensive

Shots: NICE concludes that the ICER Yescarta vs salvage CT were above £50,000 per year making it expensive for use  NICE also added considering ultra-orphan diseases that ICER for Yescarta was over £100,000 per QALY (Quality Adjusted Life)  Consideration of making Yescarta available via Cancer Drug Funds has also been dropped by the committee. Consultation […]Read More